Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. Additionally we are shipping Somatostatin Receptor 2 Kits (8) and Somatostatin Receptor 2 Proteins (7) and many more products for this protein.
Showing 10 out of 57 products:
Mouse (Murine) Polyclonal SSTR2 Primary Antibody for IHC, WB - ABIN1742010
Slooter, Mearadji, Breeman, Marquet, de Jong, Krenning, van Eijck: Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. in The British journal of surgery 2001
Show all 2 references for ABIN1742010
Human Polyclonal SSTR2 Primary Antibody for IF (p), IHC (p) - ABIN738216
Sakai, Yonezawa, Yamawaki, Oyamada: Alteration of somatostatin receptor 2 expression in canine mammary gland tumor. in The Journal of veterinary medical science / the Japanese Society of Veterinary Science 2015
Show all 2 references for ABIN738216
Human Polyclonal SSTR2 Primary Antibody for WB - ABIN611199
Perry, Hustad, Swing, OSullivan, Jenkins, Copeland: The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. in Nature genetics 1998
Somatostatin (show SST Antibodies) directly promoted spontaneous contractions of the circular muscle of macaque intestine via mediation of SSTR2 in myenteric nerve plexus between the longitudinal and the circular muscle.
5-HT(1A (show HTR1A Antibodies)), SST (show SST Antibodies)(1), and SST (show SST Antibodies)(2) receptors mediate nonadrenergic IPSPs in the noncholinergic (VIP (show Vip Antibodies)) secretomotor neurons of the submucous plexus of the guinea pig ileum.
although the limited number of cases with adequate term follow-up, SSTR (show SSTR3 Antibodies)-2A expression could be a prognostic factor and somatostatin (show SST Antibodies) analogs therapeutic candidate for SmCCs of the bladder as these tumors show high percentage of SSTR (show SSTR3 Antibodies)-2A expression
SSTR2 expression was tested in GH-secreting adenomas from 60 patients with acromegaly who had undergone pituitary surgery, 36 of whom had received octreotide with varying levels of response. Its expression was not correlated with baseline or post-octreotide GH or IGF-1 (show IGF1 Antibodies) levels or tumor volume.
Filamin-A (show FLNA Antibodies) is required to mediate SSTR2 effects in pancreatic neuroendocrine tumours
Data showed that the distribution of somatostatin (show SST Antibodies) receptor (SSTR (show SSTR3 Antibodies)) subtypes among the 199 pancreatic neuroendocrine tumors (PNETs) was: SSTR2 (54.8%), SSTR1 (show SSTR1 Antibodies) (53.3%), SSTR4 (show SSTR4 Antibodies) (51.8%), SSTR5 (show SSTR5 Antibodies) (33.7%), and SSTR3 (show SSTR3 Antibodies) (28.6%).
SSTR2 promoter hypermethylation might be associated with the risk and progression of laryngeal squamous cell carcinoma in males.
VPA was observed to stimulate the expression of somatostatin receptor type 2 (SSTR2).
Results show that histological subtyping of pituitary tumor correlated with SSTR2, E cadherin (show CDH1 Antibodies) and p27kip protein levels and these may serve as useful biomarkers for prognosis.
there is an elevation in CXCR4 (show CXCR4 Antibodies) and a decrease in SSTR2A expression with increasing malignancy in gastroenteropancreatic neuroendocrine neoplasms
mir (show MLXIP Antibodies)-185 regulates the expression of SSTR2 in GH-secreting pituitary adenoma. The staining intensity of SSTR2 is stronger in adenoma samples than controls.
Data indicate that somatostatin (show SST Antibodies) receptor scintigraphy (SRS (show SMS Antibodies)) and immunohistochemical results for somatostatin (show SST Antibodies) and dopamine receptors sstr2, sstr3 (show SSTR3 Antibodies), sstr5 (show SSTR5 Antibodies) and D2R (show DRD2 Antibodies) were compared in neuroendocrine neoplasms tissues.
Loss of sst2 from pancreatic tissues activates PI3K signaling via AKT (show AKT1 Antibodies), leading to activation of NF-kappaB (show NFKB1 Antibodies), amplification of oncogenic KRAS signaling, increased expression of CXCL16 (show CXCL16 Antibodies), and pancreatic tumor formation.
The expression and localization of the three receptors (SSTR3 (show SSTR3 Antibodies)-SSTR5 (show SSTR5 Antibodies)) in wild-type (WT), single-knockout (SSTR1 (show SSTR1 Antibodies) KO) and double-knockout SSTR1 (show SSTR1 Antibodies)/SSTR2 (DKO) mice, are reported.
SST2 expression protects against gentamicin-induced auditory hair cell loss in the mammalian inner ear.
Knock-down of SSTR2 leads to loss of pluripotency in murine embryonic stem cells.
Inhibition of the Sstr2 receptor reversed the anticonvulsant effect mediated by cortistatin-14 (show CORT Antibodies).
OCT-P407 induces mRNA expression of SSTR-2 and caspase-3 and decreases that of VEGF in mice.
The study encourages the use of liver tissue SSR2 (show SSR2 Antibodies) protein and mRNA as a reliable tumor marker for liver cancer
when activated by SST (show SST Antibodies)-14, SSTR2A internalizes and recycles via the Golgi, which requires ECE-1 (show ECE1 Antibodies) degradation of SST (show SST Antibodies)-14 and receptor dissociation from beta-arrestins
Findings suggest that somatostatin (show SST Antibodies) and its receptors (SSTR2 and SSTR5 (show SSTR5 Antibodies)) are important markers in the regulation and development of Sertoli cell.
The aim of this study was to validate an animal model expressing SSTR2 and to correlate the immunohistochemical (IHC) analysis with (18)F-FDG (show SMUG1 Antibodies) and (68)Ga-DOTATOC uptake in vivo.
Follicle-stimulating hormone regulates the SSTR2 protein expression in bovine granulosa cells.
SRIF (show SST Antibodies) can inhibit testosterone secretion through the sst2A receptor; local inhibitory action of SRIF (show SST Antibodies) is probably autocrine & might involve testosterone-induced increase of sst2 receptor expression in immature Leydig cells [SST2A]
Data demonstrate that urotensin II (show UTS2 Antibodies) and urotensin II-related peptide directly activate somatostatin (show SST Antibodies) receptors 2 and 5 and thus mimic the effect of somatostatin (show SST Antibodies) on its cognate receptors.
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biologic effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. SSTR2 is a member of the superfamily of receptors having seven transmembrane segments and is expressed in highest levels in cerebrum and kidney.
somatostatin receptor 2
, somatostatin type 2 receptor
, somatostatin receptor type 2
, somatostatin receptor type 2-like
, somatostatin receptor subtype 2
, somatotropin release-inhibiting factor receptor